Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism VPREB1 antagonists(V-set pre-B cell surrogate light chain 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Specifica, Inc.Startup |
Active Organization Specifica, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC12H14O4 |
InChIKeyFNHIEZKOCYDCOH-UHFFFAOYSA-N |
CAS Registry65623-82-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Preclinical | US | Specifica, Inc.Startup | 12 Dec 2022 |
B-Cell Lymphoma | Preclinical | US | Specifica, Inc.Startup | 12 Dec 2022 |